Day Breen
Neurology with Special Qualifications in Child Neurology · Chattanooga, TNNPI 1508121765
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,514 of the $7,672 with a category attached, or 84.9%. It is spread thinly across 36 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,155 and has fallen 58.6% since, to $1,305 in 2025.
Across 268 payments — averaging $28.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$2K
- Livanova USA, Inc.$2K
- Jazz Pharmaceuticals Inc.$755
- Neurelis, Inc.$731
- Greenwich Biosciences, Inc.$340
- Sunovion Pharmaceuticals Inc.$278
- plus $2K from 30 others
What the payments were for
- Travel & lodging$1,15815%
- Food & beverage$6,51485%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 69 | $1,759 |
| Livanova USA, Inc. | 8 | $1,641 |
| Jazz Pharmaceuticals Inc. | 33 | $755 |
| Neurelis, Inc. | 17 | $731 |
| Greenwich Biosciences, Inc. | 13 | $340 |
| Sunovion Pharmaceuticals Inc. | 31 | $278 |
| Eisai Inc. | 15 | $264 |
| SK Life Science, Inc. | 7 | $212 |
| Upsher-smith Laboratories LLC | 6 | $175 |
| Catalyst Pharmaceuticals, Inc. | 6 | $139 |
| Immedica Pharma US, Inc. | 5 | $137 |
| Acadia Pharmaceuticals Inc | 5 | $132 |
| AbbVie | 6 | $129 |
| Novartis | 5 | $108 |
| Aucta Pharmaceuticals, Inc. | 4 | $97 |
| Sumitomo Pharma America, Inc. | 7 | $91 |
| Genentech USA, Inc. | 3 | $78 |
| Azurity Pharmaceuticals, Inc. | 4 | $78 |
| Genentech, Inc. | 1 | $65 |
| Otter Pharmaceuticals, LLC | 2 | $53 |
| AstraZeneca | 2 | $44 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Sarepta Therapeutics, Inc. | 1 | $31 |
| Saol Therapeutics Inc. | 2 | $30 |
| PTC Therapeutics, Inc. | 2 | $29 |
| Supernus Pharmaceuticals, Inc. | 2 | $29 |
| Biocodex, Inc. | 1 | $24 |
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $24 |
| Teva Pharmaceuticals USA, Inc. | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $23 |
| Sanofi | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Medtronic | 1 | $18 |
| Mallinckrodt Enterprises LLC | 1 | $17 |
| Zogenix Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VNS Therapy$1,597
- VALTOCO$349
- Briviact$101
How this compares
$7,672 in reported general payments places this provider in the 75th percentile of 47 neurology with special qualifications in child neurology providers in Tennessee.
See all neurology with special qualifications in child neurology providers in Tennessee →
Other neurology with special qualifications in child neurology in Chattanooga
- Thomas IrelandChattanooga$120K
- Lewis MillerChattanooga$8K
- Laura ThomasChattanooga$3K
- Jesus Pina GarzaNashville$1.4M
- James WhelessMemphis$1.2M
- Richard FinkelMemphis$353K
- Jeffrey NeulNashville$127K
- James FryNashville$80K
- Willie AndersonJohnson City$26K
- William BurnetteNashville$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.